Sobi Announces FDA Acceptance of New Drug Application for Avatrombopag (DOPTELET®) for the Treatment of Pediatric Immune Thrombocytopenia
December 12, 2024 06:59 ET
|
Sobi, Inc.
WALTHAM, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB (Sobi®), today announced that the U.S. Food and Drug Administration...
Sobi to present new data across its immunology portfolio at the ACR Convergence 2024
November 07, 2024 06:59 ET
|
Sobi, Inc.
WALTHAM, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB (Sobi®), today announced the presentation of four abstracts that...
Sobi to present new myelofibrosis data at the ASCO 2024 Annual Meeting
May 24, 2024 16:15 ET
|
Sobi, Inc.
Sobi will present three abstracts that highlights data from its myelofibrosis treatment option at ASCO.
Sobi Receives US FDA Fast Track Designation for Emapalumab-lzsg being investigated in Macrophage Activation Syndrome
May 24, 2024 15:16 ET
|
Sobi, Inc.
FDA has granted Fast Track designation to emapalumab-lzsg for the potential first therapeutic option in patients with MAS
Health Canada Approves DOPTELET (avatrombopag) for Two Indications in Thrombocytopenia
November 06, 2023 13:07 ET
|
Sobi, Inc.
Health Canada Approves DOPTELET (avatrombopag) for Two Indications in Thrombocytopenia
Annals of Rheumatic Diseases Publishes Results from Phase 2 Study of emapalumab in Patients with Secondary HLH/Macrophage Activation Syndrome
April 04, 2023 07:00 ET
|
Sobi, Inc.
WALTHAM, Mass., April 04, 2023 (GLOBE NEWSWIRE) -- Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB (Sobi®) (STO:SOBI), today announced that the Annals of Rheumatic...